IDAHO FALLS, Idaho, May 21, 2026 /PRNewswire/ — Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB:INIS) (“Radnostix” or the “Company”), a manufacturer of radioisotope-focused products for medical, industrial, and research applications, today announced its financial results for the first quarter ended March 31, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.
First Quarter 2026 Financial and Operational Summary
- Total revenue decreased 27% to $2.38 million from $3.24 million in the first quarter of 2025, driven by recall impacts, isotope shortages, and Co60 down time.
- Gross profit decreased 43% to $1.15 million from $2.03 million in the prior-year period, reflecting recall impacts and changes in labor cost allocation.
- Cash and cash equivalents stood at $1.35 million at quarter-end (down from $1.70 million at December 31, 2025), with net cash used in operating activities of $72,442.
- Completed construction and received initial NRC license amendment for a dedicated Calibration & Reference Products manufacturing facility, positioning the Company for significant capacity expansion and product portfolio growth in 2026.
- Completed repair and retrofit of Cobalt-60 hot cell, adding 15 to 20 years of life to the asset. Restarted commercial activities in Q1 2026 after more than 5 months of down time.
- Executed mutual termination of the DUF6 asset sale agreement; Radnostix regained full control of these strategic assets amid the global nuclear energy boom and will evaluate development options, including potential license amendments for expanded uranium-related activities.
Shahe Bagerdjian, President and Chief Executive Officer, commented: “The first quarter reflected several operational and supply-chain headwinds that materially impacted our results. The two voluntary recalls in our Theranostics segment were unexpected and have hampered our revenues and margins for Q1 and will impact Q2. We believe the recall impacts should not extend beyond Q2. The planned hot cell maintenance, while necessary for quality and long-term reliability, created short-term revenue pressure which should be alleviated in Q2 and beyond. We are executing on closing out our corrective actions for the FDA observations, restoring I-131 capsule inventory, qualifying additional isotope suppliers across the segments, and returning Cobalt operations to full capacity. These steps, combined with our new facility investments and new product launches, are designed to strengthen our manufacturing resilience and position the Company for more stable performance going forward.”
2026 Outlook
- Strategic evaluation of the DUF6 assets to capitalize on renewed global interest in uranium fuel cycle services (Q2 2026).
- Full commercial launch of the EasyFill Automated Capsule System and RadVent products (both targeted for Q3 2026).
- Continued expansion of the Calibration & Reference Products facility and product line.
- Submitting a I-131 GMP API drug master file (Q4 2026) for theranostics applications for existing and new customers.
|
Three Months ended March 31, |
||||||||||||||||
|
2026 |
2025 |
$ Change |
% Change |
|||||||||||||
|
Sale of product |
$ |
2,378,924 |
$ |
3,238,900 |
$ |
(859,976) |
-27 % |
|||||||||
|
Gross profit |
1,150,948 |
2,032,037 |
(881,089) |
-43 % |
||||||||||||
|
Total Operating Expense |
2,460,980 |
2,097,053 |
146,702 |
|
||||||||||||